GlassScriptPhysician profile
Janice M Vrona
NPI 1033156377
$5,012.31
in general payments reported to CMS, 2019-2025
32 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $1,129 · 2023: $893 · 2024: $1,223 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $692.87 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Genzyme Corporation | $629.60 | 2021-2025 | |
| Celgene Corporation | $527.14 | 2022-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $404.98 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $310.71 | 2022-2025 | Keytruda, Keytruda Qlex |
| Blueprint Medicines Corporation | $279.42 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $242.48 | 2022-2025 | |
| Emd Serono, INC. | $194.05 | 2023-2025 | Bavencio |
| Daiichi Sankyo INC. | $167.57 | 2024-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $160.72 | 2022-2025 | |
| Argenx US, INC. | $145.00 | 2025 | |
| Servier Pharmaceuticals LLC | $142.64 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $107.86 | 2024-2025 | Xpovio |
| Amgen INC. | $99.91 | 2022-2023 | Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $83.54 | 2024-2025 | Enhertu, Lynparza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $78.99 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Aadi Bioscience, INC. | $72.94 | 2023-2024 | Fyarro |
| Jazz Pharmaceuticals INC. | $72.51 | 2024-2025 | |
| Coherus Oncology, INC. | $70.92 | 2024-2025 | Loqtorzi |
| Alexion Pharmaceuticals, INC. | $66.12 | 2023-2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $64.80 | 2025 | |
| Puma Biotechnology, INC. | $57.85 | 2023-2024 | |
| Genentech USA, INC. | $57.82 | 2024-2025 | Polivy, Tecentriq, Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.29 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $47.83 | 2023-2025 | Qinlock, Tgct |
| Lilly USA, LLC | $40.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $32.79 | 2022-2024 | Givlaari |
| Sobi, INC | $31.48 | 2022 | |
| Geron Corporation | $24.37 | 2025 | Rytelo |
| Emmaus Medical, INC. | $18.81 | 2022 | |
| Sk Life Science, INC. | $17.59 | 2021 | |
| Eisai INC. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Vrona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.